Search Beyond News…

WHO’s call for stronger hepatitis B and C response signals rising demand for diagnostics and antiviral therapies

Executive summary: WHO issued a statement on World Hepatitis Day urging greater efforts to diagnose and treat hepatitis B and C, noting that close to 300 million people are chronically infected but few are aware. The gap between infection and treatment represents a significant public‑health burden and a potential market for antivirals, diagnostics and related healthcare services.

Who is involved: World Health Organization, national health ministries, pharmaceutical companies, diagnostic test manufacturers, and healthcare providers.

Likely next: Expanded screening initiatives, possible reimbursement reforms, and accelerated adoption of hepatitis B and C therapies in the coming months.

On World Hepatitis Day 2026, the World Health Organization warned that nearly 300 million people live with chronic hepatitis B or C, yet most remain undiagnosed and untreated. The agency urged governments, health providers and industry to scale up screening, treatment access and prevention programs. This heightened focus could accelerate public‑health spending and create market opportunities for pharmaceutical and diagnostic firms.

Timeline

Analysis — what this means

Sectors affected

Key entities

Sources

Related cases

Browse the full archive →